Esoteric Testing Market Size, Share & Trends Report

Esoteric Testing Market Size, Share & Trends Analysis Report By Type (Oncology Testing, Infectious Disease Testing, Infectious Genetic Testing), By Technology, By End Use (Hospital-based Laboratories) By Region, And Segment Forecasts, 2025 - 2030

Report ID: GVR-4-68040-272-6
Number of Report Pages: 100
Format: PDF

Historical Range: 2018 - 2023
Forecast Period: 2025 - 2030
Industry: Healthcare

Market Segmentation

Esoteric Testing Type Outlook (Revenue in USD Million, 2018 - 2030)
- Oncology testing
- Infectious disease testing
- Genetic testing
- Endocrinology testing
- Toxicology testing
- Neurology testing
- Others
Esoteric Testing Technology Outlook (Revenue in USD Million, 2018 - 2030)
- Chemiluminescence immunoassay
- Enzyme-linked immunosorbent assay
- Mass spectrometry
- Real time polymerase chain reaction
- Flow cytometry
- Others
Esoteric Testing End Use Outlook (Revenue in USD Million, 2018 - 2030)
- Hospital-based laboratories
- Independent and reference laboratories
- Other
Esoteric Testing Regional Outlook (Revenue, USD Million, 2018 - 2030)
- North America
  - North America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - North America Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - North America End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - U.S.
    - U.S. Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - U.S. Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - U.S. End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Canada
    - Canada Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Canada Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Canada End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Mexico
    - Mexico Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Mexico Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Mexico End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Europe
  - Europe Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Europe Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Europe End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - UK
    - UK Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - UK Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - UK End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Germany
    - Germany Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Germany Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Germany End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - France
    - France Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - France Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - France End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Italy
    - Italy Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Italy Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Italy End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Spain
    - Spain Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Spain Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Spain End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Denmark
    - Denmark Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Denmark Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Denmark End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Sweden
    - Sweden Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Sweden Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Sweden End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Norway
    - Norway Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Norway Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Norway End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Asia Pacific
  - Asia Pacific Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Asia Pacific Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Asia Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - China
    - China Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - China Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - China End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Japan
    - Japan Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Japan Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Japan End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - India
    - India Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - India Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - India End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - South Korea
    - South Korea Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - South Korea Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - South Korea End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Australia
    - Australia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Australia Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Australia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Thailand
    - Thailand Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Thailand Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Thailand End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Latin America
  - Latin America Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Latin America Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Latin America Pacific End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - Brazil
    - Brazil Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Brazil Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Brazil End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Argentina
    - Argentina Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Argentina Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Argentina End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
- Middle East & Africa (MEA)
  - Middle East & Africa (MEA) Type Outlook (Revenue in USD Million, 2018 - 2030)
    - Oncology testing
    - Infectious disease testing
    - Genetic testing
    - Endocrinology testing
    - Toxicology testing
    - Neurology testing
    - Others
  - Middle East & Africa (MEA) Technology Outlook (Revenue in USD Million, 2018 - 2030)
    - Chemiluminescence immunoassay
    - Enzyme-linked immunosorbent assay
    - Mass spectrometry
    - Real time polymerase chain reaction
    - Flow cytometry
    - Others
  - Middle East & Africa (MEA) End Use Outlook (Revenue in USD Million, 2018 - 2030)
    - Hospital-based laboratories
    - Independent and reference laboratories
    - Other
  - South Africa
    - South Africa Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - South Africa Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - South Africa End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Saudi Arabia
    - Saudi Arabia Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Saudi Arabia Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Saudi Arabia End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - UAE
    - UAE Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - UAE Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - UAE End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other
  - Kuwait
    - Kuwait Type Outlook (Revenue in USD Million, 2018 - 2030)
      - Oncology testing
      - Infectious disease testing
      - Genetic testing
      - Endocrinology testing
      - Toxicology testing
      - Neurology testing
      - Others
    - Kuwait Technology Outlook (Revenue in USD Million, 2018 - 2030)
      - Chemiluminescence immunoassay
      - Enzyme-linked immunosorbent assay
      - Mass spectrometry
      - Real time polymerase chain reaction
      - Flow cytometry
      - Others
    - Kuwait End Use Outlook (Revenue in USD Million, 2018 - 2030)
      - Hospital-based laboratories
      - Independent and reference laboratories
      - Other

Report content

Qualitative Analysis

Industry overview
Industry trends
Market drivers and restraints
Market size
Growth prospects
Porter’s analysis
PESTEL analysis
Key market opportunities prioritized
Competitive landscape
- Company overview
- Financial performance
- Product benchmarking
- Latest strategic developments

Quantitative Analysis

Market size, estimates, and forecast from 2018 to 2030
Market estimates and forecast for product segments up to 2030
Regional market size and forecast for product segments up to 2030
Market estimates and forecast for application segments up to 2030
Regional market size and forecast for application segments up to 2030
Company financial performance

GET A FREE SAMPLE

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

Or view our licence options:

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

ESOMAR certified & member

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.